Skip to content

Efficacy of Vitamin E in Preventing Contrast-Induced Acute Kidney Injury Following Coronary Angiography

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02070679
Enrollment
284
Registered
2014-02-25
Start date
2014-02-28
Completion date
2015-06-30
Last updated
2015-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non ST Segment Elevation Myocardial Infarction, Post MI, Stable Angina, Unstable Angina

Keywords

Alpha-tocopherol, Vitamin E, Contrast-Induced Acute Kidney Injury, Coronary angiography

Brief summary

The purpose of this study is to evaluate the effect of vitamin E on preventing from incidence of contrast induced acute kidney injury (CI-AKI) in the patients who undergone coronary angiography.

Interventions

DRUGVitamin E

Sponsors

Urmia University of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. All patients whon have either stable coronary artery disease (CAD) or recent acute coronary disease (ACS) and are scheduled for coronary angiography. 2. Patients who have eGFR ≤60 ml/min/1.73 m2

Exclusion criteria

1. Allergy to contrast media 2. Cardiogenic shock 3. Pulmonary edema 4. Overt cardiac failure or left ventricular ejection fraction ≤ 30% 5. Acute kidney injury 6. The history of receiving contrast media for any medical diagnostic or therapeutic procedures during previous 5 days 7. The history of dialysis 8. Being pregnant 9. Having recent acute myocardial infarction 10. Taking antioxidants and nephrotoxic drugs including NSAID and ACE-I on previous 2 days

Design outcomes

Primary

MeasureTime frame
The development of CI-AKI in group receiving vitamin E compared with placeboWithin 72 hours after coronary angiography

Secondary

MeasureTime frame
Changes in the serum level of Cr and the amount of eGFRWithin 72 hours

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 2, 2026